Exozymes Inc. has announced detailed results from a 100-liter pilot production run of N-trans-caffeoyltyramine $(NCT)$ using its AI-enhanced enzymes, known as exozymes. The pilot, executed by Cayman Chemical as an independent external partner, demonstrated improved reaction performance at larger scales, achieving approximately 99% reaction conversion, 90% isolated yield, and 535 grams of NCT at 99.6% pharma-grade purity. These findings support the scalability and robustness of Exozymes' biomanufacturing process, with high-purity NCT now available for formulation development with commercial partners. The results have already been reported by the company.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exozymes Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1131921) on January 30, 2026, and is solely responsible for the information contained therein.